MATERIALS AND METHODS
In December 1994 and January 1995, we surveyed a sample of U.S. laboratories to determine their screening practices for E. coli O157:H7 for the years 1985 to 1994. We randomly selected 230 (2%) of the 11,548 U.S. laboratories that have applied for certification to perform highly or moderately complex tests as defined by the Clinical Laboratory Improvement Amendment of 1988. We conducted telephone interviews with the microbiology supervisor at each laboratory. For analysis, states were divided into 4 standard regions as follows: Northeast (Maine, N.H., Vt., Mass., R.I., Conn., N.Y., N.J., and Pa.); Midwest (Ohio, Ind., Ill., Mich., Wis., Minn., Iowa, Mo., N.Dak., S.Dak., Nebr., and Kans.); South (Del., Md., D.C., Va., W.Va., N.C., S.C., Ga., Fla., Ky., Tenn., Ala., Miss., Ark., La., Okla., and Tex.); and West (Mont., Idaho, Wyo., Colo., N.Mex., Ariz., Utah, Nev., Wash., Oreg., Calif., Alaska, and Hawaii). Data were analyzed by using Epi Info 5.01. The 2 test was used to determine if there was a significant difference between two groups. For continuous variables, analysis of variance was used to compare the means. All P values are two tailed.
RESULTS
We were able to contact 229 of the 230 selected laboratories. Of these, 129 (56%) performed stool cultures. One hundred seventeen (91%) were hospital based and 12 (9%) were independent laboratories. The median annual volume of all tests performed in these laboratories was 187,765 (range, 700 to 5,204,646). Thirty-six states were represented.
Thirty-eight (29%) laboratories reported screening all stools, and an additional 32 (25%) reported screening all bloody stools for E. coli O157:H7 in 1994 (Table 1) . Thus, 70 (54%) laboratories were screening at least all bloody stools for E. coli O157:H7 in 1994. Since 1985, the percentage of laboratories screening for E. coli O157:H7 has increased every year, with a marked increase in the last 3 years. From 1992 to 1994, the percentage of laboratories screening all stools for E. coli O157:H7 increased from 6 to 29% (P Ͻ 0.001), and the percentage of laboratories screening at least all bloody stools increased from 15 to 54% (P Ͻ 0.001) (Fig. 1) .
Hospital-based laboratories were significantly more likely than independent laboratories to screen at least some stools for E. coli O157:H7 (77 versus 33%; P ϭ 0.003). Laboratory size (as measured by annual test volume) was not predictive of screening for E. coli O157:H7. However, region of the country was associated with screening. In 1994, the percentages of laboratories screening all stools, by region, were as follows: Northeast, 42%; West, 50%; Midwest, 26%; and South, 13% (P ϭ 0.003). The percentages of laboratories screening at least all bloody stools, by region, were as follows: Northeast, 74%; West, 73%; Midwest, 47%; and South, 39% (P ϭ 0.007).
Among the laboratories that used bloody stools as a criterion for screening, all 32 reported using gross inspection to determine the presence of blood; in addition, 2 (6%) used microscopic inspection, 1 (3%) performed a test for occult blood, and 1 (3%) used a patient report of bloody stools as an indication that the stool was bloody.
Among the 94 laboratories that reported screening at least some stools for E. coli O157:H7, 80 (85%) used sorbitol-MacConkey agar and 14 (15%) used MacConkey or other agar and then checked colonies typical of E. coli for sorbitol fermentation. After sorbitol-negative colonies were detected, the next step varied by laboratory: 27 (29%) of laboratories performed a test to detect the O157 antigen, 45 (48%) performed biochemical tests to confirm the isolate as E. coli, and 20 (21%) sent the isolate to a reference laboratory for further testing. Of the 41 laboratories that performed both O157 antigen testing and biochemical tests to confirm the isolate as E. coli, 24 (58%) performed antigen testing first. Of the 44 laboratories that reported performing O157 antigen testing, 6 (14%) did their own H-typing. In addition, 43 (98%) of those 44 laboratories indicated that they reported positive isolates to the local or state health department.
For the 59 laboratories that did not screen at least all bloody stools for E. coli O157:H7, we asked the microbiology supervisor for the reasons why their laboratory did not do so. Thirtynine (66%) believed that the local incidence of E. coli O157:H7 infection was too low. Twenty-four (41%) thought that the cost of testing was too high, 8 (14%) said that testing took too much time, and 17 (29%) cited other reasons, including lack of physician requests for testing for the organism, low volume of stool culture requests received, and lack of familiarity with the screening method.
DISCUSSION
E. coli O157:H7 is a common cause of both sporadic and outbreak-associated diarrheal illness in the United States, causing an estimated 21,000 infections and 250 deaths each year (5) . In 1993 and 1994, 46 outbreaks of E. coli O157:H7 infection were reported to the Centers for Disease Control and Prevention (11) . Detection of E. coli O157:H7 infection by clinical microbiologists is often the first step in recognizing outbreaks. By January 1995, E. coli O157:H7 infection was a reportable disease in 32 states (11) . However, unless clinical laboratories routinely screen stool specimens for E. coli O157:H7, outbreaks are likely to go undetected, even in states in which the infection is reportable (10) .
The results of this study indicate that 18 months after the recommendation by the Association of State and Territorial Public Health Laboratory Directors that clinical laboratories screen at least all bloody stools for E. coli O157:H7 (12), only 54% of laboratories were doing so. The most common reason cited for not screening at least all bloody stools was the impression that the local incidence was too low. For laboratories that are unsure of the local isolation rate, we recommend performing a trial in which all stools submitted for culture during the warmer months are screened for E. coli O157:H7. The minimum number of stools needed to be screened depends on the point estimate of the isolation rate and on the volume of specimens received in that laboratory. Data from a U.S. multicenter study demonstrated an isolation rate for E. coli O157:H7 of 0.4% (24) . On the basis of a point estimate of 0.4% (range, 0.1 to 0.7%), a laboratory that receives 1,000 stool specimens annually would need to screen approximately 600 stools to estimate the local isolation rate with 95% confidence; a laboratory that receives 10,000 stool specimens each year would need to screen about 1,400 stools. Depending on the local isolation rate, some laboratories may find it best to culture all stools for E. coli O157:H7 during the warmer months, when these infections are most common (22, 23) , and to culture all bloody stools for E. coli O157:H7 the rest of the year.
In our study, the second most common reason for not screening at least all bloody stools for E. coli O157:H7 was an impression that the cost of testing was too high. A study in Washington State estimated the cost of culturing for E. coli O157:H7 at $1.10 per culture, or $183 per positive culture if all stools are cultured for E. coli O157:H7 (7). To decrease the cost of testing, some laboratories culture only grossly bloody stools for E. coli O157:H7, which has been estimated to reduce the cost of screening to $40 per positive culture (7). Patients infected with E. coli O157:H7 may develop diarrhea that is nonbloody, minimally blood streaked, or ''all blood and no stool'' (5). In reported outbreaks, the percentage of patients with E. coli O157:H7 infection who report bloody diarrhea has ranged from 35 to 90% (1, 29) . Defining the term ''bloody diarrhea'' is important, since the percentage of stool specimens that appear grossly bloody in the microbiology laboratory is lower than the percentage of patients reporting bloody stools or the percentage of stools testing positive for the presence of occult blood (24) .
In the United States, both sporadic cases and outbreaks of E. coli O157:H7 infection are more commonly reported from northern than southern states (14) . In our study, laboratories from southern states were significantly less likely to screen stools for E. coli O157:H7. This suggests that laboratory practices may contribute to the apparent regional differences in the incidence of E. coli O157:H7 infections.
The recommended method (9) for screening for E. coli O157:H7 is relatively simple and is based on the fact that E. coli O157:H7 does not ferment sorbitol rapidly (17) . Stool is plated on sorbitol-MacConkey agar, which contains 1% sorbitol instead of lactose. After 18 to 24 h of incubation, organisms that ferment sorbitol appear as pink colonies. Non-sorbitolfermenting organisms, including E. coli O157:H7, are colorless. If there are no sorbitol-negative colonies, the specimen needs no further testing.
If the sorbitol-MacConkey plate contains sorbitol-negative colonies, these are selected and assayed for the O157 antigen with commercially available antiserum (18) . Because of possible cross-reactions with other organisms, sorbitol-negative or- (27) ganisms that agglutinate in O157 antisera should then be biochemically identified as E. coli. Performing the O157 antigen testing before biochemical identification will save time, because antigen testing is the quicker procedure; isolates testing negative for the O157 antigen need not be biochemically identified as E. coli.
After biochemical identification of an O157-positive isolate as E. coli, a preliminary report should be issued to the clinician while the strain is forwarded to the state public health laboratory for identification or confirmation of the H7 flagellar antigen. For laboratories that perform their own H7 antigen testing, strains testing negative for the H7 antigen and nonmotile strains should also be forwarded to the state public health laboratory for toxin testing.
Screening for E. coli O157:H7 has value for clinical decision making as well as for public health action. In searching for a cause of bloody diarrhea, physicians have performed unnecessary exploratory surgery, hemicolectomies, colonoscopies, barium enemas, and appendectomies on patients subsequently shown to be infected with this pathogen (15, 20) . Public health intervention in outbreaks is crucial to prevent ongoing transmission and person-to-person spread. In the large January 1993 outbreak affecting persons in the western United States, early detection of E. coli O157:H7 infections by clinical microbiologists enabled a rapid recall of contaminated ground beef and prevented an estimated 800 infections (1) . The increasing percentage of laboratories in the United States screening all stools for E. coli O157:H7 is encouraging but is still less than 30%. Because many patients infected with the organism do not develop bloody diarrhea, we recommend that clinical laboratories screen all stools submitted for culture for E. coli O157: H7. This is consistent with recent recommendations from multidisciplinary consensus panels in both the United States (6) and the United Kingdom (31) . For laboratories in areas with a low incidence of E. coli O157:H7 infections, at least all bloody stools should be cultured for this organism.
